Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance

Molecules

Volumn 19, Issue 9, 2014, Pages 13848-13877

  Anreddy, Nagaraju ^a   Gupta, Pranav ^a   Kathawala, Rishil J ^a   Patel, Atish ^a,b   Wurpel, John N D ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporters; Chemotherapy; Modulators; Multidrug resistance; Tyrosine kinase inhibitors

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL; DRUG POTENTIATION; DRUG RESISTANCE; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84907101179     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190913848     Document Type: Review

References (157)

1. Van der Geer, P.; Hunter, T.; Lindberg, R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 1994, 10, 251-337.
2. Krause, D.S.; van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353, 172-187.
3. Pytel, D.; Sliwinski, T.; Poplawski, T.; Ferriola, D.; Majsterek, I. Tyrosine kinase blockers: New hope for successful cancer therapy. Anti-Cancer Agents Med. Chem. 2009, 9, 66-76.
4. Faivre, S.; Djelloul, S.; Raymond, E. New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol. 2006, 33, 407-420.
5. Aman, P. Fusion oncogenes in tumor development. Semin. Cancer Biol. 2005, 15, 236-243.
6. Brozik, A.; Hegedus, C.; Erdei, Z.; Hegedus, T.; Ozvegy-Laczka, C.; Szakacs, G.; Sarkadi, B. Tyrosine kinase inhibitors as modulators of atp binding cassette multidrug transporters: Substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin. Drug Metab. Toxicol. 2011, 7, 623-642.
7. Lemos, C.; Jansen, G.; Peters, G.J. Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer 2008, 98, 857-862.
8. Wang, X.K.; Fu, L.W. Interaction of tyrosine kinase inhibitors with the MDR-related ABC transporter proteins. Curr. Drug Metab. 2010, 11, 618-628.
9. Quintieri, L.; Fantin, M.; Vizler, C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv. Exp. Med. Biol. 2007, 593, 95-104.
10. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615-627.
11. Liu, Y.Y.; Han, T.Y.; Giuliano, A.E.; Cabot, M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15, 719-730.
12. Lowe, S.W.; Ruley, H.E.; Jacks, T.; Housman, D.E. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74, 957-967.
13. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor sxr coordinately regulates drug metabolism and efflux. Nat. Med. 2001, 7, 584-590.
14. Deeley, R.G.; Westlake, C.; Cole, S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86, 849-899.
15. Bradbury, P.A.; Middleton, M.R. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 2004, 15, 421-426.
16. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11, 1156-1166.
17. Ambudkar, S.V.; Kim, I.W.; Xia, D.; Sauna, Z.E. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for atp binding. FEBS Lett. 2006, 580, 1049-1055.
18. Wu, C.P.; Hsieh, C.H.; Wu, Y.S. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol. Pharm. 2011, 8, 1996-2011.
19. Locher, K.P.; Borths, E. ABC transporter architecture and mechanism: Implications from the crystal structures of btucd and btuf. FEBS Lett. 2004, 564, 264-268.
20. Dano, K. Active outward transport of daunomycin in resistant ehrlich ascites tumor cells. Biochim. Biophys. Acta 1973, 323, 466-483.
21. Kristensen, G.B.; Vergote, I.; Stuart, G.; Del Campo, J.M.; Kaern, J.; Lopez, A.B.; Eisenhauer, E.; Aavall-Lundquist, E.; Ridderheim, M.; Havsteen, H.; et al. First-line treatment of ovarian cancer FIGO stages IIB-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int. J. Gynecol. Cancer 2003, 13 (Suppl. 2), 172-177.
22. Soo, R.A.; Anderson, B.O.; Cho, B.C.; Yang, C.H.; Liao, M.; Lim, W.T.; Goldstraw, P.; Mok, T.S. First-line systemic treatment of advanced stage non-small-cell lung cancer in asia: Consensus statement from the asian oncology summit 2009. Lancet Oncol. 2009, 10, 1102-1110.
23. Oakman, C.; Pestrin, M.; Zafarana, E.; Cantisani, E.; Di Leo, A. Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag. Res. 2010, 2, 13-25.
24. Pelzer, U.; Arnold, D.; Reitzig, P.; Herrenberger, J.; Korsten, F.W.; Kindler, M.; Stieler, J.; Dorken, B.; Riess, H.; Oettle, H. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: A multicenter phase ii trial by the CONKO-study group. Cancer Chemother. Pharmacol. 2011, 68, 1173-1178.
25. Pieters, R.; Hunger, S.P.; Boos, J.; Rizzari, C.; Silverman, L.; Baruchel, A.; Goekbuget, N.; Schrappe, M.; Pui, C.H. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on erwinia asparaginase. Cancer 2011, 117, 238-249.
26. Schweighofer, C.D.; Wendtner, C.M. First-line treatment of chronic lymphocytic leukemia: Role of alemtuzumab. Onco. Targets Ther. 2010, 3, 53-67.
27. Borst, P.; Elferink, R.O. Mammalian abc transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537-592.
28. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of atp-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
29. Gottesman, M.M.; Ludwig, J.; Xia, D.; Szakacs, G. Defeating drug resistance in cancer. Discov. Med. 2006, 6, 18-23.
30. Glavinas, H.; Krajcsi, P.; Cserepes, J.; Sarkadi, B. The role of abc transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 2004, 1, 27-42.
31. Higgins, C.F. ABC transporters: From microorganisms to man. Annu. Rev. Cell Biol. 1992, 8, 67-113.
32. Shukla, S.; Wu, C.P.; Ambudkar, S.V. Development of inhibitors of ATP-binding cassette drug transporters: Present status and challenges. Expert Opin. Drug Metab. Toxicol. 2008, 4, 205-223.
33. Locher, K.P. Structure and mechanism of abc transporters. Curr. Opin. Struct. Biol. 2004, 14, 426-431.
34. Borths, E.L.; Locher, K.P.; Lee, A.T.; Rees, D.C. The structure of Escherichia coli BtuF and binding to its cognate ATP binding cassette transporter. Proc. Natl. Acad. Sci. USA 2002, 99, 16642-16647.
35. Gillet, J.P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775, 237-262.
36. Wu, C.P.; Calcagno, A.M.; Ambudkar, S.V. Reversal of abc drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr. Mol. Pharmacol. 2008, 1, 93-105.
37. Liu, F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy-A quick review. Taiwan J. Obstet. Gynecol. 2009, 48, 239-244.
38. Tiwari, A.K.; Sodani, K.; Dai, C.L.; Ashby, C.R., Jr.; Chen, Z.S. Revisiting the abcs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 2011, 12, 570-594.
39. Dean, M.; Allikmets, R. Evolution of ATP-binding cassette transporter genes. Curr. Opin. Genet. Dev. 1995, 5, 779-785.
40. Hyde, S.C.; Emsley, P.; Hartshorn, M.J.; Mimmack, M.M.; Gileadi, U.; Pearce, S.R.; Gallagher, M.P.; Gill, D.R.; Hubbard, R.E.; Higgins, C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990, 346, 362-365.
41. Walker, J.E.; Saraste, M.; Runswick, M.J.; Gay, N.J. Distantly related sequences in the alphaand beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1982, 1, 945-951.
42. Higgins, C.F.; Hiles, I.D.; Whalley, K.; Jamieson, D.J. Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems. EMBO J. 1985, 4, 1033-1039.
43. Dean, M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14, 3-9.
44. Mao, Q.; Unadkat, J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005, 7, E118-E133.
45. Sauna, Z.E.; Ambudkar, S.V. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J. Biol. Chem. 2001, 276, 11653-11661.
46. Gottesman, M.M.; Ambudkar, S.V. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 2001, 33, 453-458.
47. Holland, I.B. ABC transporters, mechanisms and biology: An overview. Essays Biochem. 2011, 50, 1-17.
48. Goldstein, L.J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S.L.; Gazdar, A.; Pirker, R.; Green, A.; Crist, W.; Brodeur, G.M.; et al. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989, 81, 116-124.
49. Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet. 2005, 6, 123-142.
50. Shi, Z.; Peng, X.X.; Kim, I.W.; Shukla, S.; Si, Q.S.; Robey, R.W.; Bates, S.E.; Shen, T.; Ashby, C.R., Jr.; Fu, L.W.; et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 2007, 67, 11012-11020.
51. Shi, Z.; Liang, Y.J.; Chen, Z.S.; Wang, X.H.; Ding, Y.; Chen, L.M.; Fu, L.W. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol. Rep. 2007, 17, 969-976.
52. Sauna, Z.E.; Smith, M.M.; Muller, M.; Kerr, K.M.; Ambudkar, S.V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr. 2001, 33, 481-491.
53. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol. Rev. 2006, 86, 1179-1236.
54. Figueroa-Gonzalez, G.; Jacobo-Herrera, N.; Zentella-Dehesa, A.; Pereda-Miranda, R. Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells. J. Nat. Prod. 2011, 75, 93-97.
55. Peng, X.X.; Tiwari, A.K.; Wu, H.C.; Chen, Z.S. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myeloid leukemia cells. Chin. J. Cancer 2011, 31, 110-118.
56. Mathias, A.A.; Hitti, J.; Unadkat, J.D. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289, R963-R969.
57. Zhou, S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38, 802-832.
58. Krumpochova, P.; Sapthu, S.; Brouwers, J.F.; de Haas, M.; de Vos, R.; Borst, P.; van de Wetering, K. Transportomics: Screening for substrates of ABC transporters in body fluids using vesicular transport assays. FASEB J. 2011, 26, 738-747.
59. Leighton, J.C., Jr.; Goldstein, L.J. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol. Oncol. Clin. North Am. 1995, 9, 251-273.
60. Perez-Sayans, M.; Somoza-Martin, J.M.; Barros-Angueira, F.; Diz, P.G.; Rey, J.M.; Garcia-Garcia, A. Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar atpases. Cancer Lett. 2010, 295, 135-143.
61. Marie, J.P. P-glycoprotein in adult hematologic malignancies. Hematol. Oncol. Clin. North Am. 1995, 9, 239-249.
62. Verrelle, P.; Meissonnier, F.; Fonck, Y.; Feillel, V.; Dionet, C.; Kwiatkowski, F.; Plagne, R.; Chassagne, J. Clinical relevance of immunohistochemical detection of multidrug resistance p-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 1991, 83, 111-116.
63. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
64. Schinkel, A.H.; Mol, C.A.; Wagenaar, E.; van Deemter, L.; Smit, J.J.; Borst, P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer 1995, 31A, 1295-1298.
65. Kuo, M.T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv. Exp. Med. Biol. 2007, 608, 23-30.
66. Leonard, G.D.; Fojo, T.; Bates, S.E. The role of abc transporters in clinical practice. Oncologist 2003, 8, 411-424.
67. Kruh, G.D.; Guo, Y.; Hopper-Borge, E.; Belinsky, M.G.; Chen, Z.S. ABCC10, ABCC11, and ABCC12. Pflügers Arch.-Eur. J. Physiol. 2007, 453, 675-684.
68. Sodani, K.; Patel, A.; Kathawala, R.J.; Chen, Z.S. Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer 2012, 31, 58-72.
69. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
70. Lovasz, N.; Ducza, E.; Gaspar, R.; Falkay, G. Ontogeny of sulfonylurea-binding regulatory subunits of katp channels in the pregnant rat myometrium. Reproduction 2011, 142, 175-181.
71. De Wet, H.; Fotinou, C.; Amad, N.; Dreger, M.; Ashcroft, F.M. The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids. FEBS J. 2010, 277, 2654-2662.
72. Kuang, Y.H.; Shen, T.; Chen, X.; Sodani, K.; Hopper-Borge, E.; Tiwari, A.K.; Lee, J.W.; Fu, L.W.; Chen, Z.S. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 2010, 79, 154-161.
73. McGrath, T.; Latoud, C.; Arnold, S.T.; Safa, A.R.; Felsted, R.L.; Center, M.S. Mechanisms of multidrug resistance in HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharmacol. 1989, 38, 3611-3619.
74. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
75. Kruh, G.D.; Belinsky, M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22, 7537-7552.
76. Chen, Z.S.; Hopper-Borge, E.; Belinsky, M.G.; Shchaveleva, I.; Kotova, E.; Kruh, G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 2003, 63, 351-358.
77. Hopper-Borge, E.; Chen, Z.S.; Shchaveleva, I.; Belinsky, M.G.; Kruh, G.D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res. 2004, 64, 4927-4930.
78. Hopper-Borge, E.A.; Churchill, T.; Paulose, C.; Nicolas, E.; Jacobs, J.D.; Ngo, O.; Kuang, Y.; Grinberg, A.; Westphal, H.; Chen, Z.S.; et al. Contribution of ABCC10 (MRP7) to in vivo paclitaxel resistance as assessed in ABCC10(-/-) mice. Cancer Res. 2011, 71, 3649-3657.
79. Hopper, E.; Belinsky, M.G.; Zeng, H.; Tosolini, A.; Testa, J.R.; Kruh, G.D. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001, 162, 181-191.
80. Takayanagi, S.; Kataoka, T.; Ohara, O.; Oishi, M.; Kuo, M.T.; Ishikawa, T. Human ATP-binding cassette transporter ABCC10: Expression profile and p53-dependent upregulation. J. Exp. Ther. Oncol. 2004, 4, 239-246.
81. Kathawala, R.J.; Wang, Y.J.; Ashby, C.R., Jr.; Chen, Z.S. Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chin. J. Cancer 2014, 33, 223-230.
82. Matsuo, H.; Takada, T.; Ichida, K.; Nakamura, T.; Nakayama, A.; Takada, Y.; Okada, C.; Sakurai, Y.; Hosoya, T.; Kanai, Y.; et al. Identification of ABCG2 dysfunction as a major factor contributing to gout. Nucleosides Nucleotides Nucleic Acids 2011, 30, 1098-1104.
83. Rocchi, E.; Khodjakov, A.; Volk, E.L.; Yang, C.H.; Litman, T.; Bates, S.E.; Schneider, E. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. 2000, 271, 42-46.
84. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D.D.; Miyake, K.; Resau, J.H.; Bates, S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 2000, 113 Pt 11, 2011-2021.
85. Ejendal, K.F.; Hrycyna, C.A. Multidrug resistance and cancer: The role of the human ABC transporter ABCG2. Curr. Protein Pept. Sci. 2002, 3, 503-511.
86. Robey, R.W.; Polgar, O.; Deeken, J.; To, K.W.; Bates, S.E. ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007, 26, 39-57.
87. Maliepaard, M.; Scheffer, G.L.; Faneyte, I.F.; van Gastelen, M.A.; Pijnenborg, A.C.; Schinkel, A.H.; van de Vijver, M.J.; Scheper, R.J.; Schellens, J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61, 3458-3464.
88. Cooray, H.C.; Blackmore, C.G.; Maskell, L.; Barrand, M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002, 13, 2059-2063.
89. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670.
90. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv. Drug Deliv. Rev. 2003, 55, 3-29.
91. Dean, M.; Allikmets, R. Complete characterization of the human abc gene family. J. Bioenerg. Biomembr. 2001, 33, 475-479.
92. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; et al. Molecular cloning of cdnas which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to abc transport genes. Cancer Res. 1999, 59, 8-13.
93. Tiwari, A.K.; Sodani, K.; Wang, S.R.; Kuang, Y.H.; Ashby, C.R., Jr.; Chen, X.; Chen, Z.S. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem. Pharmacol. 2009, 78, 153-161.
94. Chen, Z.S.; Robey, R.W.; Belinsky, M.G.; Shchaveleva, I.; Ren, X.Q.; Sugimoto, Y.; Ross, D.D.; Bates, S.E.; Kruh, G.D. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003, 63, 4048-4054.
95. Honjo, Y.; Hrycyna, C.A.; Yan, Q.W.; Medina-Perez, W.Y.; Robey, R.W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S.E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 2001, 61, 6635-6639.
96. Dai, C.L.; Liang, Y.J.; Wang, Y.S.; Tiwari, A.K.; Yan, Y.Y.; Wang, F.; Chen, Z.S.; Tong, X.Z.; Fu, L.W. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009, 279, 74-83.
97. Pozza, A.; Perez-Victoria, J.M.; Sardo, A.; Ahmed-Belkacem, A.; Di Pietro, A. Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell. Mol. Life Sci. 2006, 63, 1912-1922.
98. Ejendal, K.F.; Diop, N.K.; Schweiger, L.C.; Hrycyna, C.A. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 2006, 15, 1597-1607.
99. Bates, S.E.; Medina-Perez, W.Y.; Kohlhagen, G.; Antony, S.; Nadjem, T.; Robey, R.W.; Pommier, Y. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J. Pharmacol. Exp. Ther. 2004, 310, 836-842.
100. Janne, P.A.; Gray, N.; Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 2009, 8, 709-723.
101. Assef, Y.; Rubio, F.; Colo, G.; del Monaco, S.; Costas, M.A.; Kotsias, B.A. Imatinib resistance in multidrug-resistant k562 human leukemic cells. Leuk. Res. 2009, 33, 710-716.
102. Burger, H.; van Tol, H.; Boersma, A.W.; Brok, M.; Wiemer, E.A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104, 2940-2942.
103. Brendel, C.; Scharenberg, C.; Dohse, M.; Robey, R.W.; Bates, S.E.; Shukla, S.; Ambudkar, S.V.; Wang, Y.; Wennemuth, G.; Burchert, A.; et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21, 1267-1275.
104. Hegedus, C.; Ozvegy-Laczka, C.; Apati, A.; Magocsi, M.; Nemet, K.; Orfi, L.; Keri, G.; Katona, M.; Takats, Z.; Varadi, A.; et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 2009, 158, 1153-1164.
105. Hiwase, D.K.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.B.; Melo, J.; Kumar, S.; et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin. Cancer Res. 2008, 14, 3881-3888.
106. Huang, W.C.; Chen, Y.J.; Li, L.Y.; Wei, Y.L.; Hsu, S.C.; Tsai, S.L.; Chiu, P.C.; Huang, W.P.; Wang, Y.N.; Chen, C.H.; et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J. Biol. Chem. 2011, 286, 20558-20568.
107. Balabanov, S.; Gontarewicz, A.; Keller, G.; Raddrizzani, L.; Braig, M.; Bosotti, R.; Moll, J.; Jost, E.; Barett, C.; Rohe, I.; et al. ABCG2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011, 6, e19164.
108. Erlichman, C.; Boerner, S.A.; Hallgren, C.G.; Spieker, R.; Wang, X.Y.; James, C.D.; Scheffer, G.L.; Maliepaard, M.; Ross, D.D.; Bible, K.C.; et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001, 61, 739-748.
109. Illmer, T.; Schaich, M.; Platzbecker, U.; Freiberg-Richter, J.; Oelschlagel, U.; von Bonin, M.; Pursche, S.; Bergemann, T.; Ehninger, G.; Schleyer, E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004, 18, 401-408.
110. Mahon, F.X.; Belloc, F.; Lagarde, V.; Chollet, C.; Moreau-Gaudry, F.; Reiffers, J.; Goldman, J.M.; Melo, J.V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101, 2368-2373.
111. Mahon, F.X.; Hayette, S.; Lagarde, V.; Belloc, F.; Turcq, B.; Nicolini, F.; Belanger, C.; Manley, P.W.; Leroy, C.; Etienne, G.; et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68, 9809-9816.
112. Czyzewski, K.; Styczynski, J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma 2009, 56, 202-207.
113. Shibayama, Y.; Nakano, K.; Maeda, H.; Taguchi, M.; Ikeda, R.; Sugawara, M.; Iseki, K.; Takeda, Y.; Yamada, K. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol. Pharm. Bull. 2011, 34, 433-435.
114. He, M.; Wei, M.J. Reversing multidrug resistance by tyrosine kinase inhibitors. Chin. J. Cancer 2012, 31, 126-133.
115. Marchetti, S.; de Vries, N.A.; Buckle, T.; Bolijn, M.J.; van Eijndhoven, M.A.; Beijnen, J.H.; Mazzanti, R.; van Tellingen, O.; Schellens, J.H. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing BCRP1-/-/MDR1a/1b-/- (triple-knockout) and wild-type mice. Mol. Cancer Ther. 2008, 7, 2280-2287.
116. Agarwal, S.; Sane, R.; Gallardo, J.L.; Ohlfest, J.R.; Elmquist, W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 2010, 334, 147-155.
117. Chen, Y.; Agarwal, S.; Shaik, N.M.; Chen, C.; Yang, Z.; Elmquist, W.F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 2009, 330, 956-963.
118. Yang, J.J.; Milton, M.N.; Yu, S.; Liao, M.; Liu, N.; Wu, J.T.; Gan, L.; Balani, S.K.; Lee, F.W.; Prakash, S.; et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab. Lett. 2010, 4, 201-212.
119. Ozvegy-Laczka, C.; Cserepes, J.; Elkind, N.B.; Sarkadi, B. Tyrosine kinase inhibitor resistance in cancer: Role of ABC multidrug transporters. Drug Resist. Updat. 2005, 8, 15-26.
120. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, M.; Kurata, A.; Takeda, M.; et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279, 577-580.
121. Houghton, P.J.; Germain, G.S.; Harwood, F.C.; Schuetz, J.D.; Stewart, C.F.; Buchdunger, E.; Traxler, P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004, 64, 2333-2337.
122. Hegedus, T.; Orfi, L.; Seprodi, A.; Varadi, A.; Sarkadi, B.; Keri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 2002, 1587, 318-325.
123. Shen, T.; Kuang, Y.H.; Ashby, C.R.; Lei, Y.; Chen, A.; Zhou, Y.; Chen, X.; Tiwari, A.K.; Hopper-Borge, E.; Ouyang, J.; et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009, 4, e7520.
124. Shukla, S.; Sauna, Z.E.; Ambudkar, S.V. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008, 22, 445-447.
125. Shukla, S.; Skoumbourdis, A.P.; Walsh, M.J.; Hartz, A.M.; Fung, K.L.; Wu, C.P.; Gottesman, M.M.; Bauer, B.; Thomas, C.J.; Ambudkar, S.V. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): Evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol. Pharm. 2011, 8, 1292-1302.
126. Hiwase, D.K.; White, D.; Zrim, S.; Saunders, V.; Melo, J.V.; Hughes, T.P. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: Implications for combination TKI therapy. Leukemia 2010, 24, 658-660.
127. Tiwari, A.K.; Sodani, K.; Dai, C.L.; Abuznait, A.H.; Singh, S.; Xiao, Z.J.; Patel, A.; Talele, T.T.; Fu, L.; Kaddoumi, A.; et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 2013, 328, 307-317.
128. Giannoudis, A.; Davies, A.; Lucas, C.M.; Harris, R.J.; Pirmohamed, M.; Clark, R.E. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): Implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008, 112, 3348-3354.
129. Sen, R.; Natarajan, K.; Bhullar, J.; Shukla, S.; Fang, H.B.; Cai, L.; Chen, Z.S.; Ambudkar, S.V.; Baer, M.R. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol. Cancer Ther. 2012, 11, 2033-2044.
130. Sun, Y.L.; Kumar, P.; Sodani, K.; Patel, A.; Pan, Y.; Baer, M.R.; Chen, Z.S.; Jiang, W.Q. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol. Rep. 2014, 31, 1605-1612.
131. Zhang, H.; Wang, Y.J.; Zhang, Y.K.; Wang, D.S.; Kathawala, R.J.; Patel, A.; Talele, T.T.; Chen, Z.S.; Fu, L.W. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett. 2014, 350, 61-68.
132. Arteaga, C.L.; Johnson, D.H. Tyrosine kinase inhibitors-zd1839 (iressa). Curr. Opin. Oncol. 2001, 13, 491-498.
133. Ozvegy-Laczka, C.; Hegedus, T.; Varady, G.; Ujhelly, O.; Schuetz, J.D.; Varadi, A.; Keri, G.; Orfi, L.; Nemet, K.; Sarkadi, B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65, 1485-1495.
134. Kitazaki, T.; Oka, M.; Nakamura, Y.; Tsurutani, J.; Doi, S.; Yasunaga, M.; Takemura, M.; Yabuuchi, H.; Soda, H.; Kohno, S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005, 49, 337-343.
135. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M.J.; Moyer, M.P.; et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
136. Herbst, R.S. Erlotinib (Tarceva): An update on the clinical trial program. Semin. Oncol. 2003, 30, 34-46.
137. Dai, C.L.; Tiwari, A.K.; Wu, C.P.; Su, X.D.; Wang, S.R.; Liu, D.G.; Ashby, C.R., Jr.; Huang, Y.; Robey, R.W.; Liang, Y.J.; et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008, 68, 7905-7914.
138. Thomas, S.M.; Grandis, J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat. Rev. 2004, 30, 255-268.
139. Minocha, M.; Khurana, V.; Qin, B.; Pal, D.; Mitra, A.K. Enhanced brain accumulation of pazopanib by modulating P-gp and BCRP1 mediated efflux with canertinib or erlotinib. Int. J. Pharm. 2012, 436, 127-134.
140. Shi, Y.; Zhang, L.; Liu, X.; Zhou, C.; Zhang, S.; Wang, D.; Li, Q.; Qin, S.; Hu, C.; Zhang, Y.; et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013, 14, 953-961.
141. Wang, D.S.; Patel, A.; Shukla, S.; Zhang, Y.K.; Wang, Y.J.; Kathawala, R.J.; Robey, R.W.; Zhang, L.; Yang, D.H.; Talele, T.T.; et al. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget 2014, 5, 4529-4542.
142. Sodani, K.; Patel, A.; Anreddy, N.; Singh, S.; Yang, D.H.; Kathawala, R.J.; Kumar, P.; Talele, T.T.; Chen, Z.S. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem. Pharmacol. 2014, 89, 52-61.
143. Shukla, S.; Robey, R.W.; Bates, S.E.; Ambudkar, S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters p-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos. 2009, 37, 359-365.
144. Eskens, F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br. J. Cancer 2004, 90, 1-7.
145. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
146. Hu, S.; Chen, Z.; Franke, R.; Orwick, S.; Zhao, M.; Rudek, M.A.; Sparreboom, A.; Baker, S.D. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res. 2009, 15, 6062-6069.
147. Wang, Y.J.; Kathawala, R.J.; Zhang, Y.K.; Patel, A.; Kumar, P.; Shukla, S.; Fung, K.L.; Ambudkar, S.V.; Talele, T.T.; Chen, Z.S. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem. Pharmacol. 2014, 90, 367-378.
148. Kathawala, R.J.; Sodani, K.; Chen, K.; Patel, A.; Abuznait, A.H.; Anreddy, N.; Sun, Y.L.; Kaddoumi, A.; Ashby, C.R., Jr.; Chen, Z.S. Masitinib antagonizes ATP-binding cassette subfamily c member 10-mediated paclitaxel resistance: A preclinical study. Mol. Cancer Ther. 2014, 13, 714-723.
149. Kathawala, R.J.; Chen, J.J.; Zhang, Y.K.; Wang, Y.J.; Patel, A.; Wang, D.S.; Talele, T.T.; Ashby, C.R., Jr.; Chen, Z.S. Masitinib antagonizes ATP-binding cassette subfamily g member 2-mediated multidrug resistance. Int. J. Oncol. 2014, 44, 1634-1642.
150. Zhang, H.; Kathawala, R.J.; Wang, Y.J.; Zhang, Y.K.; Patel, A.; Shukla, S.; Robey, R.W.; Talele, T.T.; Ashby, C.R., Jr.; Ambudkar, S.V.; et al. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. Int. J. Biochem. Cell Biol. 2014, 51, 111-119.
151. Patel, A.; Tiwari, A.K.; Chufan, E.E.; Sodani, K.; Anreddy, N.; Singh, S.; Ambudkar, S.V.; Stephani, R.; Chen, Z.S. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother. Pharmacol. 2013, 72, 189-199.
152. Anreddy, N.; Patel, A.; Sodani, K.; Kathawala, R.J.; Chen, E.P.; Wurpel, J.N.; Chen, Z.S. PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm. Sin. B 2014, 4, 202-207.
153. Luke, J.J.; Hodi, F.S. Vemurafenib and braf inhibition: A new class of treatment for metastatic melanoma. Clin. Cancer Res. 2012, 18, 9-148.
154. Vispute, S.G.; Chen, J.J.; Sun, Y.L.; Sodani, K.S.; Singh, S.; Pan, Y.; Talele, T.; Ashby, C.R., Jr.; Chen, Z.S. Vemurafenib (PLX4032, Zelboraf®), a BRAF inhibitor, modulates ABCB1-, ABCG2-, and ABCC10-mediated multidrug resistance. J. Cancer Res. Updates 2013, 2, 306-317.
155. Brazzelli, V.; Grasso, V.; Borroni, G. Imatinib, dasatinib and nilotinib: A review of adverse cutaneous reactions with emphasis on our clinical experience. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 1471-1480.
156. Heuchel, R.; Berg, A.; Tallquist, M.; Ahlen, K.; Reed, R.K.; Rubin, K.; Claesson-Welsh, L.; Heldin, C.H.; Soriano, P. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl. Acad. Sci. USA 1999, 96, 11410-11415.
157. Tamura, A.; An, R.; Hagiya, Y.; Hoshijima, K.; Yoshida, T.; Mikuriya, K.; Ishikawa, T. Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: Development of in vitro high-speed screening systems. Expert Opin. Drug Metab. Toxicol. 2008, 4, 255-272.